Evaluation of methotrexate-conjugated gadolinium(III) for cancer diagnosis and treatment

References

• StoneJBDeangelisLMCancer-treatment-induced neurotoxicity – focus on newer treatmentsNat Rev Clin Oncol20161329210526391778
   PubMed Web of Science ®Google Scholar
• JoergerMHuitemaADIllerhausGFerreriAJRational administration schedule for high-dose methotrexate in patients with primary central nervous system lymphomaLeuk Lymphoma201253101867187522530664
   PubMed Web of Science ®Google Scholar
• AngelovLDoolittleNDKraemerDFBlood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experienceJ Clin Oncol200927213503350919451444
   PubMed Web of Science ®Google Scholar
• SolimanRKGamalSAEssaAAOthmanMHPreoperative Grading of Glioma Using Dynamic Susceptibility Contrast MRI: Relative Cerebral Blood Volume Analysis of Intra-tumoural and Peri-tumoural TissueClin Neurol Neurosurg2018167869229471287
   PubMed Web of Science ®Google Scholar
• MaximovIITonoyanASProninINDifferentiation of glioma malignancy grade using diffusion MRIPhys Med201740243228712716
   PubMed Web of Science ®Google Scholar
• NarangAKChaichanaKLWeingartJDProgressive Low-Grade Glioma: Assessment of Prognostic Importance of Histologic Reassessment and MRI FindingsWorld Neurosurg20179975175727108796
   PubMed Web of Science ®Google Scholar
• FirouzniaSSabetrasekhPAhmadianAMultimodal MRI Techniques and Their Importance in Frameless Navigation Biopsy for Brain GliomaIran J Radiol2017144e65721
   Web of Science ®Google Scholar
• BlystadIWarntjesJBMSmedbyÖLundbergPLarssonEMTisellAQuantitative MRI for analysis of peritumoral edema in malignant gliomasPLoS One2017125e017713528542553
   PubMed Web of Science ®Google Scholar
• LeuKOttGALaiAPerfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II–III diffuse gliomasJ Neurooncol2017134117718828547590
   PubMed Web of Science ®Google Scholar
• ChanKWongWSmall molecular gadolinium(III) complexes as MRI contrast agents for diagnostic imagingCoord Chem Rev200725117–2024282451
   Web of Science ®Google Scholar
• WernerEJDattaAJocherCJRaymondKNHigh-relaxivity MRI contrast agents: where coordination chemistry meets medical imagingAngew Chem Int Ed Engl200847458568858018825758
   PubMed Web of Science ®Google Scholar
• MajorJLMeadeTJBioresponsive, cell-penetrating, and multimeric MR contrast agentsAcc Chem Res200942789390319537782
   PubMed Web of Science ®Google Scholar
• ChengWHaedickeIENofieleJComplementary strategies for developing Gd-free high-field T1 MRI contrast agents based on Mn(III) porphyrinsJ Med Chem201457251652024328058
   PubMed Web of Science ®Google Scholar
• ChongHSSongHALimSA novel cholic acid-based contrast enhancement agent for targeted MRIBioorg Med Chem Lett20081872505250818337094
   PubMed Web of Science ®Google Scholar
• LiYLiuGLouXChenZMaLIntra-individual comparison of different gadolinium-based contrast agents in the quantitative evaluation of C6 glioma with dynamic contrast-enhanced magnetic resonance imagingSci China Life Sci2017601111528078511
   PubMed Web of Science ®Google Scholar
• Aydın TekdaşDGarifullinRŞentürkBDesign of a Gd-DOTA-phthalocyanine conjugate combining MRI contrast imaging and photosensitization properties as a potential molecular theranosticPhotochem Photobiol20149061376138625131633
   PubMed Web of Science ®Google Scholar
• WuBLuSTZhangLJZhuoRXXuHBHuangSWCodelivery of doxorubicin and triptolide with reduction-sensitive lipid-polymer hybrid nanoparticles for in vitro and in vivo synergistic cancer treatmentInt J Nanomedicine2017121853186228331310
   PubMed Web of Science ®Google Scholar
• WuBLiXQHuangTMRI-guided tumor chemo-photodynamic therapy with Gd/Pt bifunctionalized porphyrinBiomater Sci2017591746175028657073
   PubMed Web of Science ®Google Scholar
• WuBWanBLuSTNear-infrared light-triggered theranostics for tumor-specific enhanced multimodal imaging and photothermal therapyInt J Nanomedicine2017124467447828670120
   PubMed Web of Science ®Google Scholar
• TanMYeZLindnerDBrady-KalnaySMLuZRSynthesis and evaluation of a targeted nanoglobular dual-modal imaging agent for MR imaging and image-guided surgery of prostate cancerPharm Res20143161469147623471641
   PubMed Web of Science ®Google Scholar
• ZhouZWuXKresakAGriswoldMLuZRPeptide targeted tripod macrocyclic Gd(III) chelates for cancer molecular MRIBiomaterials201334317683769323863450
   PubMed Web of Science ®Google Scholar
• ZhangPZhangYLiBCell-assembled nanoclusters of MSC-targeting Gd-DOTA-peptide as a T2 contrast agent for MRI cell trackingJ Pept Sci2018244–5e307729582508
   PubMed Web of Science ®Google Scholar
• WangHSunDLiaoHSynthesis and characterization of a bimodal nanoparticle based on the host-guest self-assembly for targeted cellular imagingTalanta201717181528551157
   PubMed Web of Science ®Google Scholar
• LammersTAimeSHenninkWEStormGKiesslingFTheranostic nanomedicineAcc Chem Res201144101029103821545096
   PubMed Web of Science ®Google Scholar
• KelkarSSReinekeTMTheranostics: combining imaging and therapyBioconjug Chem201122101879190321830812
   PubMed Web of Science ®Google Scholar
• ZhangJLiYZhangQHaoXWangSEffects of gadolinium on proliferation, differentiation and calcification of primary mouse osteoblasts in vitroJ Rare Earths2012308831834
   Web of Science ®Google Scholar
• AbreyLEMoskowitzCHMasonWPIntensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysisJ Clin Oncol200321224151415614615443
   PubMed Web of Science ®Google Scholar
• BatchelorTCarsonKO’NeillATreatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07J Clin Oncol20032161044104912637469
   PubMed Web of Science ®Google Scholar
• ChoiYJParkHLeeJSMethotrexate elimination and toxicity: MTHFR 677C.T polymorphism in patients with primary CNS lymphoma treated with high-dose methotrexateHematol Oncol201735450450927781293
   PubMed Web of Science ®Google Scholar
• FritschKKasendaBSchorbEHigh-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study)Leukemia201731484685227843136
   PubMed Web of Science ®Google Scholar
• Hoang-XuanKBessellEBrombergJDiagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-OncologyLancet Oncol2015167e322e33226149884
   PubMed Web of Science ®Google Scholar
• OkitaYNaritaYMiyakitaYHealth-related quality of life in outpatients with primary central nervous system lymphoma after radiotherapy and high-dose methotrexate chemotherapyMol Clin Oncol20165317918527602217
   PubMedGoogle Scholar
• WellerMWickWAldapeKGliomaNat Rev Dis Primers201511501727188790
   PubMed Web of Science ®Google Scholar
• EsmaeiliMStensjøenALBerntsenEMSolheimOReinertsenIThe Direction of Tumour Growth in Glioblastoma PatientsSci Rep201881119929352231
   PubMed Web of Science ®Google Scholar
• SchuenkePPaechDKoehlerCFast and Quantitative T1ρ-weighted Dynamic Glucose Enhanced MRISci Rep201774209328169369
   PubMed Web of Science ®Google Scholar
• XuesongDWeiXHengLEvaluation of neovascularization patterns in an orthotopic rat glioma model with dynamic contrast-enhanced MRIActa Radiol20175891138114627956462
   PubMed Web of Science ®Google Scholar
• KhodadadeiFSafarianSGhanbariNMethotrexate-loaded nitrogen-doped graphene quantum dots nanocarriers as an efficient anticancer drug delivery systemMater Sci Eng C Mater Biol Appl20177928028528629019
   PubMed Web of Science ®Google Scholar
• VakilinezhadMAAlipourSMontaseriHFabrication and in vitro evaluation of magnetic PLGA nanoparticles as a potential Methotrexate delivery system for breast cancerJ Drug Deliv Sci Technol201844467474
   Web of Science ®Google Scholar
• MaestáINiteckiRHorowitzNSEffectiveness and toxicity of first-line methotrexate chemotherapy in low-risk postmolar gestational trophoblastic neoplasia: The New England Trophoblastic Disease Center experienceGynecol Oncol2018148116116729092742
   PubMed Web of Science ®Google Scholar
• ParkJALeeYJKoIOIoKImproved tumor-targeting MRI contrast agents: Gd(DOTA) conjugates of a cycloalkane-based RGD peptideBiochem Biophys Res Commun20144553–424625025449282
   PubMed Web of Science ®Google Scholar
• XiaoYXueRYouTGadolinium-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid conjugate of arabinogalactan as a potential liver-targeting magnetic resonance imaging contrast agentCarbohydr Res201439591424995911
   PubMed Web of Science ®Google Scholar
• LiYHanZRoelleSSynthesis and Assessment of Peptide Gd-DOTA Conjugates Targeting Extradomain B Fibronectin for Magnetic Resonance Molecular Imaging of Prostate CancerMol Pharm201714113906391528976766
   PubMed Web of Science ®Google Scholar